Trial Profile
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- 05 Jul 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 29 Jun 2011 Planned End Date changed from 1 May 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 28 Oct 2010 Planned End Date changed from 1 Dec 2008 to 1 May 2011 as reported by ClinicalTrials.gov.